GRB2 and hepatocellular carcinoma: Recent studies have highlighted the aberrant expression of GRB2 across multiple malignancies, including HCC, glioblastoma, colorectal carcinoma, cholangiocarcinoma, pancreatic ductal adenocarcinoma, and gastric cancer [20–22].